Inhibrx Biosciences Inc (INBX)

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR...

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May...

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential...

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line...

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire SAN...

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line...

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results PR Newswire SAN DIEGO, March 19...

Inhibrx Announces Participation in Upcoming Scientific Conference

Inhibrx Announces Participation in Upcoming Scientific Conference PR Newswire SAN DIEGO, March 2, 2026...

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the...

Inhibrx Reports Third Quarter 2025 Financial Results

Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire SAN DIEGO, Nov. 14, 2025 SAN DIEGO...

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire SAN DIEGO, Nov. 4, 2025...

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109...

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart...

Form 8-K - Current report

Inhibrx Reports Second Quarter 2025 Financial Results

Inhibrx Reports Second Quarter 2025 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2025 SAN DIEGO, Aug. 13...